SECAUCUS, N.J., Sept. 4, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced an advanced pharmacogenomic (PGx) laboratory test ...

CEO Jim Davis reported a nearly 15% revenue growth for Q4, including 5% organic growth, and close to 7% revenue growth for the full year, supported by eight acquisitions. He highlighted the Advanced ...

Quest Diagnostics DGX is well-poised to grow in the coming quarters, supported by its value-creating, strategic acquisitions. The company’s Advanced Diagnostics offerings deliver and scale innovative ...

Quest Diagnostics DGX invests in advanced diagnostics to deliver and scale innovative services that improve patient care and drive growth. The company seeks growth through disciplined, value-accretive ...

We are proud to invest in tools that elevate our standard of care and help more people live longer, healthier lives.”— ...

Quest Diagnostics Inc.’s DGX investments in Advanced Diagnostics are paying off, aiming to deliver and scale innovative services that improve patient care and drive growth. The company focuses on ...

Quest Diagnostics raised its full year 2025 guidance, with Samad providing, "Revenues are expected to be between $10.8 billion and $10.92 billion. Reported EPS is now expected to be in a range of ...

These drives reflect our commitment to community health, not just in February, but year-round—especially as we look ...

BETTER DIAGNOSTIC BUSINESS: Contractors and technicians are seeing a simplification of troubleshooting as well as potential increases in business and job accuracy. January 28, 2019 The job of HVACR ...